AZD 3355
- Generic Name
- AZD 3355
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
- Indication
Investigated for use/treatment in gastroesophageal reflux disease (GERD).
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Estimate Effect of 4 Different Doses of AZD3355 on Reflux Episodes, Which Patients With Gastroesophageal Reflux Disease (GERD) May Experience
- First Posted Date
- 2010-01-06
- Last Posted Date
- 2011-06-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT01043185
- Locations
- 🇺🇸
Research Site, Oklahoma City, Oklahoma, United States
Renal Impairment Study
- First Posted Date
- 2009-03-17
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 23
- Registration Number
- NCT00863161
- Locations
- 🇸🇪
Research Site, Lulea, Sweden
🇸🇪Research, Uppsala, Sweden
AZD3355 Dose-escalation Study in Healthy Males
- First Posted Date
- 2008-09-23
- Last Posted Date
- 2010-12-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00757419
- Locations
- 🇸🇪
Research Site, Gothenburg, Sweden
TLESR-impedance Study in Patients
- First Posted Date
- 2008-08-28
- Last Posted Date
- 2013-07-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 27
- Registration Number
- NCT00743444
Validation of Patient-reported Outcomes Measures for the Assessment of Gastroesophageal Reflux Disease (GERD) Symptoms
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-23
- Last Posted Date
- 2011-06-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 478
- Registration Number
- NCT00703534
- Locations
- 🇺🇸
Research Site, West End, Wisconsin, United States
Study to Compare Different Formulations of AZD3355
- First Posted Date
- 2008-06-03
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 48
- Registration Number
- NCT00688402
- Locations
- 🇸🇪
Research Site, Varvsgatan, Lulea, Sweden
Drug Interaction Study Between AZD3355 and Nexium
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-26
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 30
- Registration Number
- NCT00684190
- Locations
- 🇸🇪
Research Site, Uppsala, Sweden
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2013-03-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 244
- Registration Number
- NCT00394472
- Locations
- 🇷🇴
Research Site, Targu Mures, Romania
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath